GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GRAIL (Nasdaq: GRAL) granted inducement equity awards in the form of restricted stock units (RSUs) covering an aggregate of 34,350 shares of common stock to 56 newly hired non-executive employees.
Rhea-AI Summary
GRAIL (Nasdaq: GRAL) granted inducement equity awards in the form of restricted stock units (RSUs) covering an aggregate of 34,350 shares of common stock to 56 newly hired non-executive employees.
The RSUs, issued under GRAIL's Inducement Equity Incentive Plan pursuant to Nasdaq Listing Rule 5635(c)(4), vest over about four years, with 25% vesting on May 31, 2027 and annually thereafter, subject to continued employment.
Positive
- None.
Negative
- None.
Details
News Market Reaction – GRAL
In the May 28 session, GRAL gained 3.50%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Current price
- $69.04
- Pre-news trading level
- Inducement RSU shares
- 34,350 shares
- Aggregate RSUs granted to new non-executive employees
- Employees receiving RSUs
- 56 employees
- Recently hired non-executive staff
- RSU vesting period
- Approximately 4 years
- Overall RSU vesting schedule
- Initial vesting tranche
- 25% on May 31, 2027
- First RSU vesting date and proportion
- 52-week high
- $118.84
- 52-week trading range high
- 52-week low
- $29.95
- 52-week trading range low
- Market cap
- $2,959,528,253
- Pre-news equity value
Historical Context
-
Jefferies healthcare conference presentation announcement with webcast availability.
-
Q1 2026 revenue growth, Galleri volume gains, and FDA PMA review acceptance.
-
BofA Securities health care conference presentation scheduling and webcast details.
-
Announcement of timing for Q1 2026 results release and conference call.
-
Plan to present large NHS-Galleri and PATHFINDER 2 datasets at ASCO 2026.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
restricted stock units financial
rsus financial
nasdaq listing rule 5635(c)(4) regulatory
inducement equity incentive plan financial
restricted stock award agreement financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of GRAIL, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with GRAIL, pursuant to Nasdaq Listing Rule 5635(c)(4).
The RSUs vest over an approximately four year period, with
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in
For more information, visit grail.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302783559.html
SOURCE GRAIL, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.